URGN

$18.59

Post-MarketAs of Mar 17, 8:00 PM UTC

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$18.59
Potential Upside
5%
Whystock Fair Value$19.52
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technolog...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$905.00M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.37
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.31

Recent News

Simply Wall St.
Mar 5, 2026

UroGen Weighs ENVISION Success And Expanded Loan In Bladder Cancer Push

UroGen Pharma (NasdaqGM:URGN) reported new Phase 3 ENVISION trial analyses for ZUSDURI in recurrent low grade intermediate risk non muscle invasive bladder cancer, showing strong efficacy across risk groups. The company highlighted high complete response rates and durable benefit in a patient population with limited treatment options. UroGen also secured an expanded US$250 million non dilutive term loan with a fixed interest rate and no financial covenants to support clinical and commercial...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 2, 2026

UroGen Pharma Ltd (URGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...

UroGen Pharma Ltd (URGN) reports a 21% revenue increase, driven by successful product launches, despite a widening net loss and increased operational costs.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 2, 2026

Urogen Pharma Q4 Earnings Call Highlights

Urogen Pharma (NASDAQ:URGN) executives used the company’s fiscal 2025 earnings call to highlight early commercial momentum for newly launched Zusduri, continued growth from its established product Jelmyto, and a strengthened balance sheet following a refinancing with Pharmakon Advisors. Management a

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 2, 2026

UroGen (URGN) Q4 2025 Earnings Call Transcript

Joining me today are Elizabeth A. Barrett, President and Chief Executive Officer; Mark P. Schoenberg, Chief Medical Officer; David Lin, Chief Commercial Officer; and Christopher Degnan, Chief Financial Officer. On today's call, we will be making certain forward-looking statements.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 2, 2026

Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of +18.18% and +6.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.